KRAS and non-small cell lung carcinoma: The clinical implications of AKT isoforms require consideration, especially in light of our findings that an AKT1 selective inhibitor significantly reduced survival in NSCLC cell lines harboring K-ras mutations to a greater extent the pan-AKT inhibitor, MK-2206.